Frazier Life Sciences Management, L.P.
Q2 2024 13F-HR Holdings
Net value change ($000)
-232,326
(-9.8%)
New positions
8
Sold out positions
9
Turnover %
18.5%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q1 2024
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| MIRM | 58,913 | 36.1% |
| ERAS | 38,270 | NEW |
| ANAB | 34,009 | 167.9% |
| IRON | 30,216 | 61.8% |
| AGIO | 22,303 | 145.8% |
| RARE | 17,468 | NEW |
| MREO | 15,845 | NEW |
| IMTX | 13,392 | NEW |
| SVRA | 12,954 | 65.0% |
| Elevation Oncology, Inc. | 7,988 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| ALPINE IMMUNE SCIENCES, INC. | -124,113 | -100.0% |
| NAMS | -54,287 | -18.8% |
| APLS | -52,030 | -100.0% |
| JBIO | -35,628 | -100.0% |
| ORIC | -27,674 | -48.6% |
| GPCR | -26,967 | -100.0% |
| MGNX | -23,587 | -64.8% |
| Deciphera Pharmaceuticals, Inc. | -22,900 | -100.0% |
| TARS | -21,828 | -33.6% |
| ADVM | -15,119 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|